[
  {
    "sentence": "This unique pathogenesis encompasses three principal pathways (Figure 1) [15]: hypercoagulability associated with brain cancer, inflammatory and immunological dysregulation, and cancer-specific factors such as tumor compression, angioinvasion, infection, and treatment-related complications.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 1 illustrates the dynamic interplay of these mechanisms, highlighting their synergistic role in stroke pathophysiology, while also contributing to cancer initiation and progression.2.1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The hypercoagulable state in cancer arises from tumor-mediated upregulation of procoagulants and simultaneous suppression of natural anticoagulant pathway (Figure 2) [3].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Together, these mechanisms suggest that the NTME present in brain cancer promotes cellular and molecular pathways that predispose the brain to infarction, potentially exacerbating cerebral damage (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This unique pathogenesis encompasses three principal pathways (Figure 1) [15]: hypercoagulability associated with brain cancer, inflammatory and immunological dysregulation, and cancer-specific factors such as tumor compression, angioinvasion, infection, and treatment-related complications.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 1 illustrates the dynamic interplay of these mechanisms, highlighting their synergistic role in stroke pathophysiology, while also contributing to cancer initiation and progression.2.1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The hypercoagulable state in cancer arises from tumor-mediated upregulation of procoagulants and simultaneous suppression of natural anticoagulant pathway (Figure 2) [3].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Together, these mechanisms suggest that the NTME present in brain cancer promotes cellular and molecular pathways that predispose the brain to infarction, potentially exacerbating cerebral damage (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This unique pathogenesis encompasses three principal pathways (Figure 1) [15]: hypercoagulability associated with brain cancer, inflammatory and immunological dysregulation, and cancer-specific factors such as tumor compression, angioinvasion, infection, and treatment-related complications.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 1 illustrates the dynamic interplay of these mechanisms, highlighting their synergistic role in stroke pathophysiology, while also contributing to cancer initiation and progression.2.1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The hypercoagulable state in cancer arises from tumor-mediated upregulation of procoagulants and simultaneous suppression of natural anticoagulant pathway (Figure 2) [3].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Together, these mechanisms suggest that the NTME present in brain cancer promotes cellular and molecular pathways that predispose the brain to infarction, potentially exacerbating cerebral damage (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This unique pathogenesis encompasses three principal pathways (Figure 1) [15]: hypercoagulability associated with brain cancer, inflammatory and immunological dysregulation, and cancer-specific factors such as tumor compression, angioinvasion, infection, and treatment-related complications.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 1 illustrates the dynamic interplay of these mechanisms, highlighting their synergistic role in stroke pathophysiology, while also contributing to cancer initiation and progression.2.1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The hypercoagulable state in cancer arises from tumor-mediated upregulation of procoagulants and simultaneous suppression of natural anticoagulant pathway (Figure 2) [3].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Together, these mechanisms suggest that the NTME present in brain cancer promotes cellular and molecular pathways that predispose the brain to infarction, potentially exacerbating cerebral damage (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This unique pathogenesis encompasses three principal pathways (Figure 1) [15]: hypercoagulability associated with brain cancer, inflammatory and immunological dysregulation, and cancer-specific factors such as tumor compression, angioinvasion, infection, and treatment-related complications.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 1 illustrates the dynamic interplay of these mechanisms, highlighting their synergistic role in stroke pathophysiology, while also contributing to cancer initiation and progression.2.1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The hypercoagulable state in cancer arises from tumor-mediated upregulation of procoagulants and simultaneous suppression of natural anticoagulant pathway (Figure 2) [3].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Together, these mechanisms suggest that the NTME present in brain cancer promotes cellular and molecular pathways that predispose the brain to infarction, potentially exacerbating cerebral damage (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This unique pathogenesis encompasses three principal pathways (Figure 1) [15]: hypercoagulability associated with brain cancer, inflammatory and immunological dysregulation, and cancer-specific factors such as tumor compression, angioinvasion, infection, and treatment-related complications.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 1 illustrates the dynamic interplay of these mechanisms, highlighting their synergistic role in stroke pathophysiology, while also contributing to cancer initiation and progression.2.1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The hypercoagulable state in cancer arises from tumor-mediated upregulation of procoagulants and simultaneous suppression of natural anticoagulant pathway (Figure 2) [3].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Together, these mechanisms suggest that the NTME present in brain cancer promotes cellular and molecular pathways that predispose the brain to infarction, potentially exacerbating cerebral damage (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This unique pathogenesis encompasses three principal pathways (Figure 1) [15]: hypercoagulability associated with brain cancer, inflammatory and immunological dysregulation, and cancer-specific factors such as tumor compression, angioinvasion, infection, and treatment-related complications.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 1 illustrates the dynamic interplay of these mechanisms, highlighting their synergistic role in stroke pathophysiology, while also contributing to cancer initiation and progression.2.1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The hypercoagulable state in cancer arises from tumor-mediated upregulation of procoagulants and simultaneous suppression of natural anticoagulant pathway (Figure 2) [3].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Together, these mechanisms suggest that the NTME present in brain cancer promotes cellular and molecular pathways that predispose the brain to infarction, potentially exacerbating cerebral damage (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This unique pathogenesis encompasses three principal pathways (Figure 1) [15]: hypercoagulability associated with brain cancer, inflammatory and immunological dysregulation, and cancer-specific factors such as tumor compression, angioinvasion, infection, and treatment-related complications.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 1 illustrates the dynamic interplay of these mechanisms, highlighting their synergistic role in stroke pathophysiology, while also contributing to cancer initiation and progression.2.1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The hypercoagulable state in cancer arises from tumor-mediated upregulation of procoagulants and simultaneous suppression of natural anticoagulant pathway (Figure 2) [3].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Together, these mechanisms suggest that the NTME present in brain cancer promotes cellular and molecular pathways that predispose the brain to infarction, potentially exacerbating cerebral damage (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This unique pathogenesis encompasses three principal pathways (Figure 1) [15]: hypercoagulability associated with brain cancer, inflammatory and immunological dysregulation, and cancer-specific factors such as tumor compression, angioinvasion, infection, and treatment-related complications.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 1 illustrates the dynamic interplay of these mechanisms, highlighting their synergistic role in stroke pathophysiology, while also contributing to cancer initiation and progression.2.1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The hypercoagulable state in cancer arises from tumor-mediated upregulation of procoagulants and simultaneous suppression of natural anticoagulant pathway (Figure 2) [3].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Together, these mechanisms suggest that the NTME present in brain cancer promotes cellular and molecular pathways that predispose the brain to infarction, potentially exacerbating cerebral damage (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This unique pathogenesis encompasses three principal pathways (Figure 1) [15]: hypercoagulability associated with brain cancer, inflammatory and immunological dysregulation, and cancer-specific factors such as tumor compression, angioinvasion, infection, and treatment-related complications.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 1 illustrates the dynamic interplay of these mechanisms, highlighting their synergistic role in stroke pathophysiology, while also contributing to cancer initiation and progression.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The hypercoagulable state in cancer arises from tumor-mediated upregulation of procoagulants and simultaneous suppression of natural anticoagulant pathway (Figure 2) [3].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The hypercoagulable state in cancer arises from tumor-mediated upregulation of procoagulants and simultaneous suppression of natural anticoagulant pathway (Figure 2) [3].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Together, these mechanisms suggest that the NTME present in brain cancer promotes cellular and molecular pathways that predispose the brain to infarction, potentially exacerbating cerebral damage (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Together, these mechanisms suggest that the NTME present in brain cancer promotes cellular and molecular pathways that predispose the brain to infarction, potentially exacerbating cerebral damage (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Together, these mechanisms suggest that the NTME present in brain cancer promotes cellular and molecular pathways that predispose the brain to infarction, potentially exacerbating cerebral damage (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  }
]